Nicotine Pouch Statistics 2026: Zyn Sales, Users, Quit Data

Nicotine pouch statistics 2026 track the fastest-growing segment in the entire nicotine category. Philip Morris International reported US Zyn shipment volumes of 581.4 million cans in 2024, with shipments climbing again through 2025 toward roughly 800 million, while the FDA authorized Zyn to make reduced-risk marketing claims in June 2026. This data page pulls together the sourced numbers on who uses pouches, how fast the category is growing, what strengths are actually sold, and — the honest caveat most marketing skips — what the cessation evidence does and does not say.

1. Market Size and Sales Growth

Nicotine pouches have gone from a niche Nordic snus alternative to the fastest-growing nicotine product category in the US in barely three years. The clearest hard numbers come from Philip Morris International’s own shipment reporting for Zyn, the category’s dominant brand, which has climbed steeply every quarter since 2023. Market-research estimates put the wider US pouch category in the low billions of dollars with projected annual growth around 20% over the next decade, though those projections are commercial forecasts rather than measured data and should be read as estimates.

• Zyn US shipment volume, 2024: 581.4 million cans (Philip Morris International reporting)
• 2025 direction: shipments continued climbing quarter over quarter, toward roughly 800 million cans for the year
• Category position: the fastest-growing nicotine product category in the US since 2023
• US pouch market value: estimated in the low billions of dollars (market-research estimate)
• Projected growth: around 20% annually over the coming decade (commercial forecast, not measured data)

This growth curve sits inside the broader shift the site has documented in our 2026 smoking cessation statistics hub, where nicotine product mix is changing faster than overall nicotine dependence rates.

2. Who Uses Nicotine Pouches

Zyn dominates brand share within the category, and pouch users skew toward existing nicotine users rather than nicotine-naive adults. Brand concentration is unusually high compared with most consumer product categories: in the 2025 National Youth Tobacco Survey, Zyn was by a wide margin the most commonly reported brand among students who used pouches, and adult survey work shows the same pattern.

For readers weighing pouches directly against an approved alternative, our comparison of approved NRT options and our safety explainer on whether Zyn and Velo are safe to quit with go deeper into the practical trade-offs this data page only sketches.

3. Youth Uptake Data

Youth pouch use remains low relative to vaping, and the federal surveillance data is more reassuring than most headlines suggest. The 2024 National Youth Tobacco Survey found 1.8% of US middle and high school students reported current (past-30-day) nicotine pouch use, making pouches the second most used product after e-cigarettes. The 2025 NYTS, published in Nicotine & Tobacco Research in 2026, put the figure at 1.7% across a nationally representative sample of 23,630 students — essentially flat year over year, against a backdrop of overall tobacco use falling to 7.2%.

• Current use, all middle/high schoolers (2024 NYTS): 1.8%
• Current use, all middle/high schoolers (2025 NYTS): 1.7% — no meaningful year-over-year change
• Frequent use among youth pouch users (2025): 26.3% used on 20 or more of the past 30 days
• Context: any tobacco use among students fell to 7.2% (2.01 million students) in 2025, with e-cigarettes at 5.2%
• Longer trend: the Monitoring the Future survey has reported past-30-day pouch use among older teens roughly doubling between 2023 and 2024, from a low base

The gap between “current use is low and broadly stable” and “a quarter of the teens who do use pouches use them almost daily” is the genuine story in this data. Prevalence is not the concerning number; intensity among the minority who adopt the product is.

A local news report explains the FDA’s 2026 decision letting Zyn market itself as lower-risk than cigarettes, and what that claim does and does not cover.

4. Nicotine Strength Distribution

US pouches are sold in a narrower strength range than international versions. Zyn’s mainstream US lineup centers on 3 mg and 6 mg pouches, with some brands offering higher-strength options for established users; products sold in Nordic and other European markets can reach substantially higher nicotine loads per pouch. Clinicians who work with pouch users typically recommend stepping down from the higher strength toward 3 mg as a tapering strategy when someone wants to reduce or stop.

• Common US strengths: 3 mg and 6 mg (mainstream Zyn lineup)
• Higher-strength lines: some brands sell above 6 mg in the US, and international products can go considerably higher
• Typical tapering approach: step down from the higher strength toward 3 mg pouches, then reduce frequency

5. Regulatory Status by Market

Regulation varies sharply by country, from outright bans to light-touch age restrictions. This patchwork matters for anyone reading pouch statistics across markets, since prevalence data is not comparable where the product is banned outright.

The FDA’s public register of modified risk tobacco products records the Zyn modified-risk granted order dated 30 June 2026, following a Tobacco Products Scientific Advisory Committee meeting in January 2026.

6. Dependence Markers in Pouch Users

Because pouches deliver nicotine through the oral mucosa rather than inhalation, absorption is slower than cigarettes or vapes, which manufacturers and some clinicians frame as a harm-reduction advantage. But slower absorption does not mean low dependence risk. Clinical and treatment-center reports describe a consistent pattern: tolerance builds with regular use, requiring higher doses or more frequent pouches for the same effect, and users who try to stop describe a recognizable nicotine withdrawal syndrome. The federal survey finding that 26.3% of young pouch users use them on 20 or more days a month is consistent with that picture.

• Withdrawal symptoms reported: irritability, intense cravings, anxiety, difficulty concentrating, sleep disturbance, mood changes
• Typical withdrawal onset: within a few hours of the last pouch
• Typical withdrawal duration: peaks within about a week, most symptoms ease over 2-4 weeks
• Tolerance pattern: escalation to higher strengths or more frequent use is commonly reported by treatment programs

This dependence profile is comparable in kind, though not necessarily in degree, to what’s documented across nicotine products generally — see our data on how addictive nicotine really is and our guide to what nicotine withdrawal actually feels like week by week. Readers who want a structured way down from pouches specifically should see our step-down taper plan for quitting Zyn and similar pouches, and anyone comparing pouches with the older Scandinavian product might also want our explainer on what snus is and whether it’s safer than smoking.

7. The Cessation-Evidence Gap

This is the point most pouch marketing skips: no nicotine pouch product is FDA-approved, or approved by any major regulator, as a smoking-cessation aid. The FDA’s January 2025 authorization and its 30 June 2026 modified-risk marketing order are both about relative harm compared with cigarettes for adult smokers who already use tobacco — not about efficacy for quitting nicotine altogether. A 2025 Cochrane review, the field’s gold-standard evidence synthesis, examined oral nicotine pouches for cessation or reduction of other tobacco use and concluded there is limited evidence for their use in quitting or cutting down cigarettes; it also found low-certainty evidence, from one small study, that people randomized to pouches may be slightly less likely to quit smoking than those randomized to e-cigarettes (Cochrane Database of Systematic Reviews, October 2025).

• FDA cessation approval status: none — no pouch product is approved as a quit-smoking aid
• FDA modified-risk order (30 June 2026): permits reduced-risk-versus-cigarettes marketing for adult smokers, which is distinct from a cessation claim
• Cochrane 2025 review finding: limited evidence for pouches aiding cessation or reduction of cigarette use; no evidence at all for quitting other nicotine products
• Approved alternatives with cessation evidence: NRT gum, patches, lozenges, and prescription medications, all backed by randomized-trial data

For pouch users who specifically want to stop nicotine altogether rather than switch products, our data on quit smoking success rates by method is the more evidence-backed starting point. iQuit‘s craving-log and gradual-reduction tools are built to support tapering off any nicotine product, pouches included, with money-saved tracking that updates regardless of which product you’re stepping down from.

8. Methodology and Sources

Shipment-volume figures come from Philip Morris International’s published reporting for Zyn; market-value and growth-rate figures are commercial market-research estimates and are presented as approximations rather than measured data, because independent verification of those forecasts is not publicly available. Youth prevalence data comes from the 2024 National Youth Tobacco Survey (CDC and FDA, published in MMWR) and the 2025 National Youth Tobacco Survey, published in Nicotine & Tobacco Research in 2026, supplemented by the Monitoring the Future survey for longer-run trend direction. Cessation-evidence findings are drawn from the Cochrane Database of Systematic Reviews, Oral nicotine pouches for cessation or reduction of use of other tobacco or nicotine products (October 2025). Regulatory status reflects the FDA’s public modified risk tobacco product register and publicly available government guidance in effect as of 2026. Where a precise figure could not be traced to a primary source, a qualitative description is used instead.

Frequently Asked Questions